On Thursday, BioNTech ADR stock earned an upgrade to its Relative Strength (RS) Rating, from 75 to 81.
IBD's proprietary rating identifies share price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
History reveals that the market's biggest winners tend to have an RS Rating of at least 80 as they launch their biggest runs.
Risk Management In The Stock Market: How Much Money To Invest Now
Is BioNTech Stock A Buy?
BioNTech stock is building a consolidation with a 131.49 buy point. See if the biotech stock can clear the breakout price in volume at least 40% higher than normal.
The German biotech company saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 0% to 29%. Revenue rose from -25% to 46%.
BioNTech stock holds the No. 151 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Exelixis are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
